Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Potential Bone-Seeking Radiopharmaceutical by Sodium Pyrophosphate Labeled <sup>188</sup>Rhenium (<sup>188</sup>Re-PYP) for Bone Pain Palliation.

Iranian journal of pharmaceutical research : IJPR·2025
Same author

The impact of the xSPECT reconstruction algorithms on the recovery coefficients value for small tumors: a phantom study with 177Lu.

Nuklearmedizin. Nuclear medicine·2024
Same author

Evaluating the color stability of 3D-printed resins against various solutions.

European journal of translational myology·2023
Same author

Design and performance evaluation of a slit-slat camera for 2D prompt gamma imaging in proton therapy monitoring: A Monte Carlo simulation study.

Medical physics·2023
Same author

Outcomes following transarterial radioembolization with <sup>90</sup>Y and nanoparticles loaded resin microspheres.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2022
Same author

Role of nanoparticles in transarterial radioembolization with glass microspheres.

Annals of nuclear medicine·2022

Related Experiment Video

Updated: Apr 13, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Activity estimation in radioimmunotherapy using magnetic nanoparticles.

Samira Rasaneh1, Hossein Rajabi1, Fariba Johari Daha1

  • 11 Department of Radioisotope, Nuclear science and Technology Research Institute, Tehran 14115-331, Iran ; 2 Department of Medical Physics, School of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran.

Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|May 5, 2015
PubMed
Summary

This study developed novel Lutetium-177 trastuzumab-iron oxide nanoparticles for targeted cancer therapy and improved organ activity estimation. Magnetic Resonance Imaging (MRI) provided more accurate dosimetry than SPECT imaging.

Keywords:
Radioimmunotherapy (RIT)activity estimationherceptinlutetium-177magnetic nanoparticlesmagnetic resonance imaging (MRI)

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K

Related Experiment Videos

Last Updated: Apr 13, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical therapy
  • Nanomedicine

Background:

  • Accurate estimation of radiopharmaceutical activity in tumors and organs is crucial for predicting treatment response.
  • Developing dual-acting agents for therapy and improved imaging is an ongoing challenge in nuclear medicine.

Purpose of the Study:

  • To synthesize and characterize Lutetium-177 (177Lu)-trastuzumab-iron oxide nanoparticles as a theranostic agent.
  • To evaluate the efficacy of Magnetic Resonance Imaging (MRI) for estimating organ activity compared to Single Photon Emission Computed Tomography (SPECT).

Main Methods:

  • Synthesis of 177Lu-trastuzumab-iron oxide nanoparticles.
  • Comprehensive quality control including labeling yield, size, stability, and immunoreactivity.
  • Comparative biodistribution and organ activity assessment in tumor-bearing mice using SPECT, MRI, and organ extraction.

Main Results:

  • Successful synthesis of 177Lu-trastuzumab-iron oxide nanoparticles with favorable quality control results (e.g., labeling yield 61%±2%, size 41±15 nm).
  • Demonstrated stability in buffer and blood serum, and good immunoreactivity (80%±2%).
  • MRI enabled more accurate measurement of organ activities compared to SPECT in mice bearing breast tumors.

Conclusions:

  • Co-conjugation of radiopharmaceuticals with MRI contrast agents like iron oxide nanoparticles offers a promising approach for enhanced dosimetry in nuclear medicine.
  • This dual-agent strategy facilitates more precise therapeutic monitoring and treatment planning.